Practice · Urology & Nephrology

From symptom to surgery, without the leaks.

Endourology, HoLEP, uro-oncology and transplant work-up — one integrated pipeline that stops losing patients between the OPD, dialysis unit and OT.

For Chiefs of Urology, Nephrology and Transplant Sciences at multi-organ super-specialty hospitals.

Request a Urology Pipeline Blueprint →Review case evidence

Transplant Work-up Conversions

2.4×

9-mo cohort

Endourology Case Volume

+118%

Stone disease

Robotic Uro-oncology

+92%

Case volume

Dialysis → Transplant Path

+3.1×

Internal conversion

Procedure-level demand engineering

We target the procedures that move your P&L, not the ones that fill the OPD queue.

CATCHMENT TIER · PRICE RESTATEMENT

ARPU differs materially between Metro, Tier-2 and Tier-3 catchments. Switch tier to restate every procedure band against the payer mix and package ceilings we observe in that market — not a single all-India number.

Viewing Metro / Tier-1 · Representative catchments: Delhi NCR, Mumbai, Bengaluru, Chennai, Hyderabad, Kolkata, Pune.

RIRS / PCNL (Stone Disease)

₹1.4 L–2.8 L

Acute pain + imaging-triggered funnel

HoLEP / TURP (BPH)

₹1.8 L–3.2 L

Age-cohort educational funnel

Robotic Prostatectomy

₹4.8 L–7.2 L

PSA-triggered oncology funnel

Renal Transplant Work-up

₹18 L–28 L

CKD / dialysis-unit conversion

Uro-oncology (Kidney/Bladder)

₹3.2 L–8.0 L

Biopsy-report review pathway

Reconstructive & Female Urology

₹2.0 L–4.0 L

Underserved, high-intent funnel

Methodology. Base bands reflect RDV's engagement dataset across 47 super-specialty hospitals, reconciled against CGHS/ECHS package rates, state-scheme ceilings (Ayushman Bharat PM-JAY, CMCHIS, YSR Aarogyasri) and empanelled TPA grids. Tier multipliers applied: Metro 1.00× · Tier-2 0.72× · Tier-3 0.55×. Actuals swing with payer mix, consultant-fee split and implant/consumable choice — the written Blueprint restates every band against your own HIS billing history before any spend is committed.

Clinical referral pathway

Intent → triage → consult → admission. Instrumented at every gate.

01 · Symptom-led intent
Stone pain, prostate symptoms, haematuria, CKD staging content.
02 · Report-gated triage
USG / creatinine / PSA report upload before consult booking.
03 · Consultant handoff
Urologist / nephrologist / transplant coordinator based on stage.
04 · Multi-visit orchestration
Work-up, donor coordination, cross-match and OT slotting instrumented as one flow.

Case snapshot

2.4× transplant work-ups, +118% endourology volume.

A representative RDV engagement in the Urology & Nephrology practice line. Individual results vary by catchment, clinical capacity and payer mix.

Setting: Multi-organ transplant centre, 260 beds
Duration: 12 months
Cohort: n = 1,540 uro/nephro enquiries
Outcome: 2.4× transplant work-ups, +118% endourology volume

Figures engagement-verified against hospital HIS. No outcome guarantees implied; per NMC advertising guidelines.

Why Chiefs of Urology choose RDV

Trust is earned in the operating logic, not the pitch deck.

Dialysis-unit conversion pathway

Your existing CKD patient base treated as the transplant funnel it actually is — with a documented internal SOP.

THOTA-first donor communication

All donor-facing content reviewed by empanelled counsel and mirrors state authorization committee flow. Zero regulatory ambiguity.

Report-gated consult booking

USG, creatinine, PSA upload before the consult slot is offered. Filters serious intent from window-shoppers.

Multi-visit orchestration

Work-up, cross-match, financial pre-auth and OT slotting treated as one flow — not four disconnected desks.

From an engagement

"The internal dialysis-to-transplant path was the single biggest lever. We already had the patients. We just weren't converting them."

— Chief of Nephrology & Transplant · 260-bed multi-organ centre

Attribution anonymised per client confidentiality; engagement code verifiable in the founder-led review.

Talk directly to the founding partner who ran this engagement.

Request a Urology Blueprint →

48-hour founder-led review. Fixed-scope. No lock-in.

Clinical authority

Content your clinicians will co-sign.

Transplant surgeon + nephrologist joint content
Donor coordinator SOP visible on the site
Kidney-health educational library (CKD staging)

Compliance posture

Every asset, every claim, medically reviewed.

THOTA-compliant donor communication
NMC + DCGI review of device-related content (holmium laser, robotic platform)
DPDP-grade handling of report uploads

Catchment note: Transplant corridors across GCC, East Africa and SAARC; endourology catchment across Tier-2 India stone-belt geographies.

The 21-day diagnostic

What the fixed-scope engagement actually contains — for Urology.

No mystery, no scope creep. Each week is instrumented and delivered against a checklist your MD and Chief signs.

Week 1
Dialysis-unit conversion audit; work-up-to-transplant leakage forensic.
Week 2
Endourology catchment map across stone-belt geographies.
Week 3
Uro-oncology second-opinion pathway design; PSA/haematuria funnel.
Week 4
Founder-led review with Chief of Urology & Nephrology.

Where we compound

The unfair edge — for Urology specifically.

Only consultancy with a published dialysis→transplant conversion protocol
THOTA-compliant donor communication reviewed by empanelled counsel
Stone-belt Tier-2 catchment engineering across Rajasthan, Bihar, Odisha

Practice guarantees

What we commit to in writing.

Fixed-scope diagnostic — no retainer, no annual lock-in
HIS-verified attribution — every claimed admission traceable to source
No media markup — you see raw platform invoices at cost
Founder-led — the partner who scopes the engagement does the work

Objections we hear

The three questions MDs ask before signing.

We keep our answers on the record. If yours isn't here, ask it in the qualification form — the founding partner replies personally within 48 hours.

Transplant marketing is a regulatory minefield.

Marketing donation is. Educating patients on kidney health, publishing donor coordination SOPs and supporting voluntary living-donor education for identified family relationships are not. We do only the second.

Stone disease is commoditised in our metro.

In metros, largely yes. Margin lives in stone-belt Tier-2/3 catchment, corporate insurance tie-ins and complex/staghorn cases. We move the mix, not just the volume.

We already have a transplant coordinator team.

Then the missing piece is upstream — the CKD and dialysis conversation before the coordinator is even involved. That's the layer we build.

FAQ

The questions Chiefs of Urology ask us first.

If yours isn't here, put it in the qualification form — our founding partner will answer it in the 48-hour review.

How do you grow transplant volume ethically under THOTA?+

By educating on kidney health, transparently publishing your donor coordination SOP, and building a dialysis-unit-to-transplant conversion pathway. All donor communication is THOTA-compliant and reviewed by empanelled counsel.

Is the stone-disease market too commoditised?+

In metros, largely yes on price. Margin lives in Tier-2/3 catchment, insurance-tie-ins and complex/staghorn cases. We segment accordingly.

How do you convert dialysis patients to transplant candidates?+

By instrumenting the dialysis-unit conversation — screening for candidacy, initiating work-up, and orchestrating donor conversations with a dedicated transplant coordinator. Internal conversion typically 3-4× within 12 months.

Do you work with standalone urology hospitals?+

Yes — standalone urology and multi-organ transplant centres both fit. Standalone urology particularly benefits from procedure-level demand engineering.

Next step